[go: up one dir, main page]

RU99113447A - METHOD FOR DIAGNOSIS OF METABOLIC BONE DISEASES - Google Patents

METHOD FOR DIAGNOSIS OF METABOLIC BONE DISEASES

Info

Publication number
RU99113447A
RU99113447A RU99113447/14A RU99113447A RU99113447A RU 99113447 A RU99113447 A RU 99113447A RU 99113447/14 A RU99113447/14 A RU 99113447/14A RU 99113447 A RU99113447 A RU 99113447A RU 99113447 A RU99113447 A RU 99113447A
Authority
RU
Russia
Prior art keywords
ocif
metabolic bone
bone disease
recognize
monoclonal antibody
Prior art date
Application number
RU99113447/14A
Other languages
Russian (ru)
Other versions
RU2203497C2 (en
Inventor
Казуки Яно
Фумие Кобаяси
Масааки Гото
Наохиро Васида
Эйсуке ТСУДА
Кандзи Хигасио
Йосидзи ЯМАДА
Original Assignee
Сноу Брэнд Милк Продактс Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сноу Брэнд Милк Продактс Ко., Лтд. filed Critical Сноу Брэнд Милк Продактс Ко., Лтд.
Publication of RU99113447A publication Critical patent/RU99113447A/en
Application granted granted Critical
Publication of RU2203497C2 publication Critical patent/RU2203497C2/en

Links

Claims (1)

1. Способ диагностики метаболических костных заболеваний, отличающийся тем, что метаболические костные заболевания диагностируются с помощью определения концентрации фактора, ингибирующего остеокластогенез (OCIF) во взятой биологической жидкости.1. A method for diagnosing metabolic bone diseases, characterized in that metabolic bone diseases are diagnosed by determining the concentration of an osteoclastogenesis inhibiting factor (OCIF) in a given biological fluid. 2. Способ диагностики метаболических костных заболеваний по п. 1, в котором указанная биологическая жидкость представляет собой кровь или синовиальную жидкость. 2. A method for diagnosing metabolic bone diseases according to claim 1, wherein said biological fluid is blood or synovial fluid. 3. Способ диагностики метаболических костных заболеваний по п. 1 или 2, в котором указанное метаболическое костное заболевание представляет собой остеопороз. 3. A method for diagnosing metabolic bone disease according to claim 1 or 2, wherein said metabolic bone disease is osteoporosis. 4. Способ диагностики метаболических костных заболеваний по п. 1 или 2, в котором указанное метаболическое костное заболевание представляет собой артроз. 4. A method for diagnosing metabolic bone disease according to claim 1 or 2, wherein said metabolic bone disease is arthrosis. 5. Способ диагностики метаболических костных заболеваний по п. 1 или 2, в котором указанное метаболическое костное заболевание представляет собой ревматоидный артрит. 5. A method for diagnosing metabolic bone disease according to claim 1 or 2, wherein said metabolic bone disease is rheumatoid arthritis. 6. Моноклональное антитело, одинаково распознающее и мономерный, и гомодимерный типы OCIF. 6. Monoclonal antibody that equally recognizes both monomeric and homodimeric OCIF types. 7. Моноклональное антитело, избирательно распознающее димерный тип OCIF
8. Моноклональное антитело по п. 6 или 7, в котором указанное моноклональное антитело может распознавать другой эпитоп OCIF и имеет высокое сродство, а также проявляет константу диссоциации менее 2 х 10-7 М с антигеном.7. Monoclonal antibody selectively recognizing a dimeric type of OCIF
8. The monoclonal antibody according to claim 6 or 7, wherein said monoclonal antibody can recognize another OCIF epitope and has a high affinity, and also exhibits a dissociation constant of less than 2 x 10 -7 M with antigen. 9. Набор количественного анализа для определения концентрации OCIF, включающий моноклональные антитела, которые могут распознавать другой эпитоп OCIF и имеет высокое сродство, а также проявляют константу диссоциации менее 10-9 М с антигеном и могут одинаково распознавать и мономерный тип и гомодимерный тип OCIF, и моноклональные антитела, которые могут распознавать другой эпитоп и OCIF, имеет высокое сродство, а также проявляют константу диссоциации менее 2 х 10-7 M с антигеном и могут избирательно распознавать димерный тип OCIF.9. A set of quantitative analysis for determining the concentration of OCIF, including monoclonal antibodies that can recognize another epitope of OCIF and has a high affinity, and also exhibit a dissociation constant of less than 10 -9 M with antigen and can equally recognize both the monomeric type and homodimeric type of OCIF, and monoclonal antibodies that can recognize a different epitope and OCIF have a high affinity, and also exhibit a dissociation constant of less than 2 x 10 -7 M with antigen and can selectively recognize the dimer type of OCIF.
RU99113447/14A 1997-09-24 1998-07-31 Method for diagnosing the cases of bone metabolism disorder diseases RU2203497C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP27647597 1997-09-24
JP9/276475 1997-09-24

Publications (2)

Publication Number Publication Date
RU99113447A true RU99113447A (en) 2001-04-27
RU2203497C2 RU2203497C2 (en) 2003-04-27

Family

ID=17569976

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99113447/14A RU2203497C2 (en) 1997-09-24 1998-07-31 Method for diagnosing the cases of bone metabolism disorder diseases

Country Status (16)

Country Link
US (2) US6693175B2 (en)
EP (1) EP0974671B1 (en)
JP (1) JP4268684B2 (en)
KR (1) KR100547395B1 (en)
CN (1) CN1183159C (en)
AT (1) ATE328281T1 (en)
AU (1) AU739304B2 (en)
CA (1) CA2269114A1 (en)
DE (1) DE69834719D1 (en)
HU (1) HUP0002062A3 (en)
IL (1) IL129535A (en)
NO (1) NO992472D0 (en)
NZ (1) NZ335759A (en)
RU (1) RU2203497C2 (en)
WO (1) WO1999015691A1 (en)
ZA (1) ZA986974B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
CN1183961C (en) 1998-10-28 2005-01-12 三共株式会社 Remedies for bone metabolic errors
JP3709332B2 (en) * 2000-09-14 2005-10-26 株式会社エーシーバイオテクノロジーズ Method for diagnosis of osteoporosis and / or prediction of risk of osteoporotic fracture
WO2002062990A1 (en) * 2001-02-07 2002-08-15 Sankyo Company, Limited Antibody and utilization thereof
WO2002079256A1 (en) * 2001-03-26 2002-10-10 Sankyo Company, Limited Antibody and utilization thereof
ES2337716T3 (en) * 2001-04-03 2010-04-28 Societe Des Produits Nestle S.A. OSTEOPROTEGERIN IN MILK.
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
PA8568001A1 (en) * 2002-03-01 2003-11-12 Sankyo Co PHARMACEUTICAL COMPOSITION
US7279451B2 (en) 2002-10-25 2007-10-09 Honeywell International Inc. Compositions containing fluorine substituted olefins
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
KR100545064B1 (en) * 2003-05-26 2006-01-24 김현기 Liver Cirrhosis Diagnosis Kit containing Antibody Specific to Human Primary Cancer Protein
WO2007137123A2 (en) * 2006-05-17 2007-11-29 The Research Foundation Of State University Of New York Biomechanical treatment for obesity and diabetes
WO2012051495A2 (en) 2010-10-15 2012-04-19 The Research Foundation Of State University Of New York Compositions and methods for enhancing the biological response to chemical agents and physical stimuli
RU2524616C1 (en) * 2013-01-21 2014-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Владивостокский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГОУ ВПО ВГМУ Минздрава России) Diagnostic technique for early stage of rheumatoid arthritis
GB201302257D0 (en) 2013-02-08 2013-03-27 Nobel Biocare Services Ag Method for measuring bone loss rate
CN106405064B (en) * 2016-08-30 2018-10-26 嘉兴行健生物科技有限公司 A kind of appraisal procedure of 40 years old or more women bone turnover rate
CN109540818A (en) * 2018-12-21 2019-03-29 云南农业大学 A method of based on calcium, phosphorus blood biochemical markers breeding Wuding Chicken
CN113621060B (en) * 2020-05-07 2023-07-04 浙江瑞硕生物技术有限公司 OPG antibody pair and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
CA2001373A1 (en) * 1988-10-24 1990-04-24 Bruce Caterson Methods and compositions for diagnosing, monitoring and treating the early stage of osteoarthritis
EP0513334A4 (en) 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (en) 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int REGULATORY FACTOR OF OSTEOCLAST GROWTH.
US5366859A (en) * 1991-10-31 1994-11-22 Mitsubishi Petrochemical Co., Ltd. Radioimmunoassay method
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5427954A (en) * 1992-04-29 1995-06-27 Shriner's Hospitals For Crippled Children Compositions and methods for detection and treatment of human osteoarthritis
US5578569A (en) 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
DE69427588T2 (en) 1993-09-14 2002-04-25 Merck & Co., Inc. HUMANE PROTEIN TYROSINPHOSPHATASE DECODING cDNA
WO1996000240A1 (en) * 1994-06-27 1996-01-04 Snow Brand Milk Products Co., Ltd. Novel protein and process for producing the same
AU4440496A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000318A1 (en) * 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
AU5985996A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
JPH1057071A (en) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd Novel DNA and method for producing protein using the same
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
EP0951546A2 (en) 1996-12-20 1999-10-27 The Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
DE122010000048I1 (en) 1996-12-23 2011-05-05 Immunex Corp LIGAND FOR RECEPTOR ACTIVATOR OF NF-KAPPA B, LIGAND IS A MEMBER OF THE TNF SUPERFAMILY
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins

Similar Documents

Publication Publication Date Title
RU99113447A (en) METHOD FOR DIAGNOSIS OF METABOLIC BONE DISEASES
EP0220245B1 (en) Method for determining mimotopes
Jefferis et al. Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study
Kyle Diagnostic criteria of multiple myeloma
US5688652A (en) Detection of collagen degradation in vivo
DE59008278D1 (en) Specific antibodies against Troponin T, their preparation and use in a reagent for the determination of cardiac muscle necrosis.
RU2003132446A (en) ANTI-BODY AGAINST OSTEOPONTIN AND ITS APPLICATION
NO992472L (en) Method for diagnosing metabolic bone disorders
ES2173165T3 (en) METHOD FOR OBTAINING REAGENTS FOR DIAGNOSTICS, DOSAGE AND THERAPIES BASED ON THE CLINICAL MANIFESTATIONS OF AN DISEASE.
ATE120549T1 (en) METHOD FOR DETERMINING HIV ANTIBODIES.
US6210902B1 (en) Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen
Boatin et al. Diagnostics in onchocerciasis: future challenges
CA2007336A1 (en) Diagnostic test using chimeric antibodies
KR970011852A (en) How to diagnose autoimmune disease
EP0787301B1 (en) Estimation of the fragmentation pattern of collagen in body fluids and the diagnosis of disorders associated with the metabolism of collagen
DE69909897T2 (en) Detection of antibodies against FIV using ENV / GAG polypeptides
Deng et al. Reappraisal of the specificity of the Crithidia luciliae assay for nDNA antibodies: evidence for histone antibody kinetoplast binding
ATE180894T1 (en) USE OF POLYCLONAL HUMAN ANTI-HTG AUTOANTIBODIES AS A REAGENT FOR CLINICAL DIAGNOSTICS OF THYROID AUTOIMMUNE DISEASES AND REAGENT SET FOR DETERMINATION OF ANTI-HTG AUTOANTIBODIES IN PATIENT SERA
RU2227297C2 (en) Monoclonal antibodies against s100
Levinson Kappa/lambda index for confirming urinary free light chain in amyloidosis AL and other plasma cell dyscrasias
Ruben et al. Antibodies to calmodulin during experimental Trypanosoma brucei rhodesiense infections in rabbits
KR102504175B1 (en) Peptides binding to antibodies, drug complex, biosensor and analyzing method using the same
US5472848A (en) Methods to aid in the diagnosis of multiple sclerosis
US5593898A (en) Diagnostic method for the immunological determination of NCAM
Hoffmann et al. Serological distance coefficients